Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K current report with the SEC on April 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO Craig Collard’s amended agreement increases severance to 100% salary plus bonus outside change-in-control periods.
HERON THERAPEUTICS, INC. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Craig Collard’s amended agreement increases severance to 100% salary plus bonus outside change-in-control periods
- Change-in-control termination protection: 200% salary and bonus, full equity acceleration, and 24 months’ healthcare coverage
- CFO Ira Duarte, CDO William Forbes, and COO Mark Hensley receive comparable 24-month change-in-control protections
- Equity acceleration upon a change in control raises potential transaction-related compensation costs
- New 24-month non-compete and non-solicitation covenants strengthen retention protections but may constrain post-departure flexibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HERON THERAPEUTICS, INC. /DE/ 8-K filings
Get the next HRTX 8-K as it lands
Follow HRTX for push alerts, or ask the research agent what this filing means.